Ribbon Bio is a synthetic biology company developing algorithm-driven technology to synthesize long, complex DNA molecules. The company's proprietary MiroSynth™ platform combines intelligent algorithms with enzymatic assembly and automated laboratory processes to produce high-fidelity synthetic DNA constructs up to 20 kb in length, with claimed full sequence flexibility and error-proof manufacturing.
The platform serves researchers and biopharmaceutical companies working on mRNA therapies, CAR-T cell therapies, and other advanced biological applications. Ribbon Bio raised EUR 18 million in Series A funding and operates from Vienna, Austria, with a presence in the United States.
The company is expanding its commercial operations and manufacturing capabilities to address growing demand across the synthetic biology sector. Its focus on computational biotechnology, enzymatic assembly, and automation reflects a technical approach to producing pristine synthetic DNA at scale.
